Aim Immunotech Stock Price, News & Analysis

AIM ImmunoTech Inc. (NYSE American: AIM) announced the IRB approval for its Phase 2 study, AMP-518, evaluating Ampligen as a treatment for post-COVID conditions. The trial will assess the drug's efficacy in reducing fatigue among patients through various metrics, including the PROMIS® Fatigue Score. About 80 subjects aged 18 to 60 will be enrolled across 10 centers in the U.S. AIM expects to commence patient enrollment and dosing in Q2 2023. This development emphasizes the company's commitment to addressing a significant unmet medical need related to chronic fatigue-like symptoms following COVID-19.

AIM ImmunoTech Inc. (NYSE American: AIM) reported its financial results for the fourth quarter and full year 2022, highlighting solid progress in its clinical pipeline with 12 active programs. The company's cash reserves decreased from $48.3 million in 2021 to $34.2 million in 2022. R&D expenses declined to $7.0 million, while general and administrative expenses rose to $13.1 million. AIM aims to advance Ampligen for various critical health needs and has set numerous milestones for 2023, including studies in pancreatic cancer and post-COVID conditions. The company launched a new website for enhanced shareholder communication.

AIM ImmunoTech Inc. (NYSE American: AIM) has appointed Nancy K. Bryan to its Board of Directors, enhancing its leadership team during a crucial development phase. With over 25 years in the life sciences sector, including roles at major pharmaceutical companies and as President of BioFlorida Inc., Bryan brings extensive marketing and commercialization expertise. Her addition aligns with AIM's goal of increasing diversity on the board and is expected to drive growth for its lead product, Ampligen. AIM focuses on therapeutics for cancers, immune disorders, and viral diseases, including COVID-19.

AIM ImmunoTech Inc. (NYSE American: AIM) has announced its financial results reporting for the full year ending December 31, 2022, scheduled for March 31, 2023. Following the release, the management will conduct its inaugural quarterly conference call on April 3, 2023, to discuss the results. AIM focuses on developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19. The company’s leading product, Ampligen® (rintatolimod), is an investigational immuno-modulator with potential applications in significant health issues.

AIM ImmunoTech Inc. (NYSE American: AIM) announced positive findings from a recent presentation regarding Ampligen, revealing its potential as both a prophylactic and an early-onset therapy against Ebola virus disease (EVD). Presented at the International Conference on Antiviral Research, Ampligen showed significant immunological responses and protective results in mouse models, demonstrating a survival rate of 100% in lethal challenges. The company plans to file for Investigational New Drug applications to further study Ampligen for EVD treatment and prevention. Ampligen has also received Orphan Drug status from the FDA and EMA.

On March 8, 2023, AIM ImmunoTech (NYSE American: AIM) announced the publication of new data demonstrating that its drug Ampligen (rintatolimod) effectively inhibits the Ebola virus. Published in Antiviral Research, the study indicates that Ampligen offers a dual mechanism of action: enhancing innate immune responses and inactivating the EBOV lethal factor. Prior research showed 100% protection in a mouse model. Ampligen holds Orphan Drug Designation for Ebola from both the European Medicines Agency and the FDA, offering market exclusivity upon approval. AIM plans to file Investigational New Drug applications to explore Ampligen's use for Ebola treatment and prevention.

AIM ImmunoTech (AIM) reported significant operational and clinical advancements in its 2022 stockholder letter, highlighting successful trials for various cancer therapies and a commitment to future milestones. In 2022, AIM achieved several key developments, including IND clearance for a Phase 2 study targeting advanced pancreatic cancer and positive data from its clinical programs. The company is positioned to pursue multiple regulatory milestones in 2023, including commencing Phase 2 studies for post-COVID conditions and locally advanced pancreatic cancer. AIM emphasizes continued engagement with investors and scientific communities, showcasing a strategy for advancing clinical pipelines as it aims to deliver long-term stakeholder value.

AIM ImmunoTech Inc. (NYSE American: AIM) has announced the opening of its first clinical site for the AMP-270 Phase 2 study, evaluating Ampligen for locally advanced pancreatic cancer (LAPC). This randomized study compares the efficacy of Ampligen to a no-treatment control after FOLFIRINOX therapy. The trial aims to enroll approximately 90 subjects across 30 centers in the U.S. and Europe. CEO Thomas K. Equels emphasized the potential of Ampligen to set a new standard of care for LAPC, highlighting ongoing recruitment efforts at prominent cancer institutions.

AIM ImmunoTech Inc. (NYSE American: AIM) announced its participation in a virtual event on February 21, 2023, titled “Long Covid: What Will It Take To Accelerate Therapeutic Progress?” The event seeks to advance research on Long Covid and related diseases. CEO Thomas K. Equels will discuss the clinical development of Ampligen for ME/CFS and Long COVID. Preliminary results from Ampligen's treatment of Long COVID patients showed a statistically significant reduction in fatigue (p=0.002). The FDA has cleared AIM for a Phase 2 study of Ampligen for Post-COVID Conditions, with patient enrollment expected to begin in Q1 2023.